

Janet T. Mills  
Governor

Jeanne M. Lambrew, Ph.D.  
Commissioner



Maine Department of Health and Human Services  
Office of MaineCare Services - Pharmacy Unit  
11 State House Station  
Augusta, Maine 04333-0011  
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)  
Fax: (207) 287-8601

## DUR COMMITTEE AGENDA

Date: Tuesday, November 5, 2024  
Time: 1:00PM to 5:00PM  
Location: Virtual:  
To Dial in: 1-207-209-4724  
Phone Conference ID: 453617402#  
Teams link: [Click here to join the meeting](#)  
In-Person: 109 Capitol Street  
11 State House Station Rooms A and B  
Augusta, Maine 04333

- 1) Closed Session (1:00pm- 2:30pm)- Board members only (a separate invitation to be sent)
- 2) MaineCare Updates – Anne-Marie Toderico, PharmD
- 3) Public Comments
- 4) Old Business
  - Approve September Meeting Minutes
- 5) Revised clinical criteria
  - Vasomotor Symptoms Agents
- 6) New Business (open session).
  - Present 2025 Meeting Schedule
  - Present 2025 RetroDUR Potential Initiatives
  - Open session to review categories subject to potential changes. Additional categories without changes for 2025 will not be reviewed and will be voted on.

Antiasthmatic – Anti-inflammatory Agents  
Anticonvulsants  
Antipsychotic- LAI/Atypicals  
Antiretrovirals  
CV Heart Failure  
Bronchodilators, Beta Agonists  
Cytokine and CAM Antagonists  
DME- Diabetic Supplies  
Derm Atopic Dermatitis  
GI- IBS/ OIC/CIC/ Antiemetics  
Growth Hormones  
Hematopoietics/CSF/ESA  
Hemophilia  
Hyperuricemia and Gout  
Hypoglycemics, Incretin Memetics

Hypoglycemics, Insulins & Related Agents  
Hypoglycemics, SGLT2 Inhibitor & Misc. Agents  
Migraine  
Multiple Sclerosis Agents  
Ophthalmic Anti-inflammatories  
Opiate Dependence & Overdose Treatments  
Resp. Anticholinergic/Asthma/COPD/Steroid/Misc  
Sickle Cell Disease Agents  
Stimulants & Related Agents  
Urinary Antispasmodic  
Antineoplastics- Biosimilar PDL  
Mineralocorticoid Receptor Antagonist  
Muscular Dystrophy Corticosteroids  
Otic Steroid  
Platelet Aggregate Inhibitors

- 7) FDA Safety Alerts
  - [FDA adds warning about rare occurrence of serious liver injury with use of Veozah \(fezolinetant\) for hot flashes due to menopause | FDA](#)
  - [FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbrta from the market due to safety concerns | FDA](#)
- 8) Next Meeting (Tuesday, December 10, 2024, 6 – 8p)
- 9) Adjournment: 5:00pm